At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
BI 730357 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of BI 730357 on the Pharmacokinetics of Rosuvastatin, Digoxin, Metformin and Furosemide Given as a Cocktail - an Open-label, Non-randomised, 2-period Fixed-sequence Trial in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating BI 730357, CRESTOR®, and 3 other interventions for Healthy. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The main objective of this trial is to investigate the effect of BI 730357 under steady state conditions on the pharmacokinetics of digoxin, furosemide, metformin and rosuvastatin given as a cocktail (Reference, R: cocktail alone; Test T: cocktail given under steady state conditions of BI 730357).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartOct 2020
Primary CompletionJan 2021
TodayJul 2026
First PostedOct 19, 2020
Enrollment StartOct 20, 2020
Primary CompletionJan 11, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.7 years ago
Interventions
BI 730357drug
Film-coated tablet
CRESTOR®drug
Film-coated tablet
Lenoxin®drug
Tablet
MetfoLiquid GeriaSan®drug
Oral solution
Lasix®drug
Oral solution